The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.
A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.
In an effort to localize the effects of anesthesia, researchers have turned to magnetic nanoparticles to target the delivery of ropivacaine in a proof-of-concept animal study.
At MIT, researchers have developed nanoparticles that can carry as many as three cancer drugs at a time in a precise ratio.
Pennsylvania wound-care specialist Alliqua pulled in $15 million from a private funding round and another $5.3 million from the exercise of warrants, giving the company a $20.3 million windfall overall.
As drug delivery becomes more and more dependent on nanotechnology for treatments such as chemotherapy, it's important that scientists in the field understand the implications of the tiny vehicles and what factors might play a part, for good or bad, in their delivery potential.
Researchers at the University at Buffalo have put the "pop" into drug delivery by releasing compounds from liposomes called nanoballoons that break open upon being hit with a laser.
Novaliq is beginning an early-stage study of its cyclosporin eye drop for dry eye syndrome. Although cylosporin is poorly soluble in water, Novaliq's platform allows for a clear solution as opposed to an emulsion, making it more suitable for delivering drugs in the eye.
DNA nanorobots that have proven their drug-delivering performance in early in vitro clinical trials have now demonstrated that they can do the same operations in a living cockroach.
Dartmouth researcher Jack Hoopes has demonstrated that magnetic nanoparticle hyperthermia could be a possible treatment for breast cancer, as he presented in a new preclinical study at the American Association for Cancer Research annual meeting in San Diego.
In a study presented at the American Association for Cancer Research in San Diego this week, researchers from the University of Colorado described a cancer-killing method that uses gold nanorods to target tumor cells in the bladder.
AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.
Researchers at the Italian Universtiy of Udine have developed small nanorobots with a "flap" designed to open and release compounds with unprecedented precision.
In a study published in the journal Nature Materials, University of Pennsylvania scientists describe a hydrogel they developed that is designed to be applied directly to heart muscle to reduce continuing damage after a heart attack.
Engineers have developed a method to measure the density of nanomaterials as they come into contact with cells and tissue. Beyond the safety aspect of being able to determine the amount of exposure a patient has had to nanoparticles, the method could also be used to help develop new drug delivery systems that make use of the tiny materials.
Many drug delivery systems incorporate complex compounds designed to deliver precise doses to a desired target. Researchers at the University of California, San Diego, though, have developed a platform that uses as its main delivery function a substance familiar to us all: water.
A small molecular pump devised by researchers from the U.S., Russia and Puerto Rico could offer a new insulin delivery method for people with diabetes, using enzymes to convert chemical energy into a propulsion system for drugs.
Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale.
A new patch-like device designed by engineers at the University of Texas at Austin boasts a number of functions, including drug delivery for patients with movement disorders such as epilepsy or Parkinson's disease.
California drugmaker Avanir Pharmaceuticals touted the FDA's acceptance of its application for an inhaled migraine treatment after a pivotal trial.